Putting The Spotlight On G1 Therapeutics Inc (GTHX)

G1 Therapeutics Inc (NASDAQ:GTHX) currently has a daily average trading volume of 1.30M but it saw 737109 shares traded in last market. With a market cap of 167.82M USD, the company’s current market price of $3.21 came rising about 0.63 while comparing to the previous closing price of $3.19. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.14 and as low as $1.08.

Taking a look at 20-day trading activity of G1 Therapeutics Inc (GTHX) gives us an average price of $4.09, while its current price level is -47.72% below from 52-week high level whereas it is 197.22% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $4.24 while that of 200 days or SMA-200 reads an average of $2.88. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.91% during that period while stretching the period over a month that increases to 9.36%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 28.48 which implies that the stock is in oversold territory.

The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the JP Morgan which upgraded the stock as “Neutral” in its note to investors issued on January 30, 2023, recommending a price target of between $7 and $10 for it. JP Morgan issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $20 and $19.

Over the week, GTHX’s stock price is moving -3.89% down while it is -24.82% when we observe its performance for the past one month. Year-to-date it is 5.25% up and over the past year, the stock is showing an upside performance of 13.83%.

The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of 0.14 beat the consensus estimate of -0.22 for the same. In next quarter, company is expected to be making quarterly sales of $18.01M as analysts are expecting the sales for current fiscal year at $72.26M and seeing the company making $98.93M in sales next year. Moreover, analysts are in estimates of $16.45M for current-quarter revenue.

Currently, G1 Therapeutics Inc’s total number of outstanding shares is 51.93M. Company’s return on investment (ROI) stands at -44.41% and return on equity (ROE) at -84.13%. Stock’s beta reads 1.59. Stock has a price to book (P/B) ratio of 6.04 while price to sale or P/S ratio amounts to 2.00. Its return on asset (ROA) is -23.18% on average.